Applications of butylidenephthalide

Abstract

Applications of butylidenephthalide (BP), comprising the use of BP in providing a kit for promoting differentiation of stem cells into brown adipose cells, and the use of BP in preparing a medicament, wherein the medicament is used for inhibiting the accumulation of white adipose cells, promoting the conversion of white adipose cells into brown adipose cells, inhibiting weight gain and/or reducing the content of triglycerides, glucose, and total cholesterol in blood.

1 . A kit for promoting the differentiation of a stem cell into a brown-like adipose cell, comprising the following components:
 (1) a conditional medium, comprising a basic medium and an ingredient capable of inducing the differentiation of a stem cell into an adipose cell; and   (2) butylidenephthalide (BP).   
     
     
         2 . The kit as claimed in  claim 1 , wherein the ingredient is selected from the group consisting of rosiglitazone, insulin, 3-isobutyl-1-methylxanthine (IBMX), dexamethasone, and combinations thereof. 
     
     
         3 . A method for inhibiting the accumulation of white fat and/or promoting the conversion of white fat into brown fat, comprising administering to a subject in need an effective amount of butylidenephthalide (BP). 
     
     
         4 . A method for inhibiting the accumulation of white fat, promoting the conversion of white fat into brown fat, inhibiting weight gain and/or reducing the contents of triglycerides, glucose and total cholesterol in blood, comprising administering to a subject in need an effective amount of butylidenephthalide (BP), and the butylidenephthalide (BP) is administered with at least one of a mesenchymal stem cell and a brown-like adipose cell. 
     
     
         5 . The method as claimed in  claim 4 , which is for anti-obesity and/or preventing metabolic syndrome associated with obesity. 
     
     
         6 . The method as claimed in  claim 5 , wherein the metabolic syndrome is at least one of diabetes mellitus, cerebrovascular disease, cardiovascular disease, hypertension and nephropathy. 
     
     
         7 . The method as claimed in  claim 4 , wherein the mesenchymal stem cell is an adipose stem cell. 
     
     
         8 . The method as claimed in  claim 3 , wherein the butylidenephthalide (BP) is administered at an amount ranging from 30 mg (as BP)/kg-body weight to 2000 mg (as BP)/kg-body weight per day. 
     
     
         9 . The method as claimed in  claim 4 , wherein the butylidenephthalide (BP) is administered at an amount ranging from 30 mg (as BP)/kg-body weight to 2000 mg (as BP)/kg-body weight per day. 
     
     
         10 . The method as claimed in  claim 5 , wherein the mesenchymal stem cell is an adipose stem cell. 
     
     
         11 . The method as claimed in  claim 6 , wherein the mesenchymal stem cell is an adipose stem cell. 
     
     
         12 . The method as claimed in  claim 5 , wherein the butylidenephthalide (BP) is administered at an amount ranging from 30 mg (as BP)/kg-body weight to 2000 mg (as BP)/kg-body weight per day. 
     
     
         13 . The method as claimed in  claim 6 , wherein the butylidenephthalide (BP) is administered at an amount ranging from 30 mg (as BP)/kg-body weight to 2000 mg (as BP)/kg-body weight per day. 
     
     
         14 . The method as claimed in  claim 7 , wherein the butylidenephthalide (BP) is administered at an amount ranging from 30 mg (as BP)/kg-body weight to 2000 mg (as BP)/kg-body weight per day. 
     
     
         15 . The method as claimed in  claim 8 , wherein the butylidenephthalide (BP) is administered at an amount ranging from 30 mg (as BP)/kg-body weight to 2000 mg (as BP)/kg-body weight per day. 
     
     
         16 . The method as claimed in  claim 9 , wherein the butylidenephthalide (BP) is administered at an amount ranging from 30 mg (as BP)/kg-body weight to 2000 mg (as BP)/kg-body weight per day.